
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is attractive because its royalty base from Breo and Anoro provides durable, high-margin cash flow through 2030, with roughly $1.0B in expected royalty revenue over the next five years helping fund growth and shareholder returns. Its operating portfolio is also accelerating, as 2Q26 IST revenue rose 26% y/y to $36.6M, led by Giapreza and XacDuro, while internally marketed products exceeded $180M in LTM revenue as of March 2026 and grew 37% y/y in 1Q26. The company also has multiple value-creating catalysts from Nortiva Bio’s LYNX platform, strategic investments such as Armata, and a strong balance sheet with $603.1M in cash at 1Q26, supporting further capital deployment and repurchases.
Bears say
Innoviva is facing a weaker fundamental backdrop as royalty revenue came in at $59.8M, down 11% year over year, with GSK citing U.S. pricing pressure and softer inhaled respiratory demand, while FactSet consensus for 2026/2027 has already fallen about 6% to 7%. The company also has limited offset from newer products, as Zevtera sales were only about $0.4M, up 3.5% year over year, and expectations were cut materially from a prior peak of roughly $72M to about $39M in 2033E amid launch and clinical execution risk. In addition, Innoviva’s valuation is exposed to volatile strategic holdings, including a roughly 28% decline in Armata shares in 3Q26 that implies about a $45M loss plus $17M to $20M in warrant value, while ongoing competition and capital-allocation risk could further pressure future royalty growth and returns.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Innoviva (INVA) Forecast
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares